Article Sidebar
Published:
Sep 30, 2026Keywords:
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All materials published in the Babcock University Medical Journal (BUMJ) are protected by the Copyrights Laws of Nigeria. The Authors reserves copyright of their published articles but gives all the users (Authors, Readers, and Researchers) free access to all materials published online under the provisions of the Creative Commons Attribution Non-Commercial 4.0 License. However, permissions are granted to copy, use, and distribute the contents only for non-commercial but academic and scientific purposes with the proviso that the source of the content is appropriately cited and credited.
Main Article Content
Serum irisin as a Novel Biomarker in Diabetic Retinopathy: A Case-Control Study
Abstract
Objective: This study aims to evaluate irisin as a novel biomarker for Diabetic Retinopathy (DR) by measuring serum irisin levels in patients with DR, patients without DR, and a control group. Additionally, it aims to determine serum irisin levels across the clinical stages of DR and to investigate their relationship with disease severity.
Methods: The study comprised 240 participants.Participants were divided into three major groups: 80 patients with DR, 80 patients without DR, and 80 in the control group.The subdivided DR group was divided into four stages (n = 20 per stage). Standard procedures and techniques were used to measure serum irisin, lipid profile, fasting blood sugar (FBS), and glycated haemoglobin (HbA1c), and the data were analysed statistically.
Results: The primary result serum irisin levels were significantly lower (69.68 ± 19.77 ng/ml) in patients with DR than in patients without DR and in the control group (82.17 ± 9.24 ng/ml) (120.66 ± 24.07 ng/ml), respectively, with a highly significant difference (p < 0.001).The study’s further subgroup analysis within the DR group shows that irisin levels exhibit highly significant differences (p < 0.001), with a gradual decline across the clinical stages of DR. Irisin is negatively correlated with FBS, HbA1c, Triglycerides,Very Low-Density Lipoprotein, and duration of diabetes mellitus.ROC analysis showed that serum irisin discriminated between DR and non-DR patients, with an AUC of 0.83.
Conclusion: The present study findings concluded that irisin levels were significantly lower in patients with DR. Additionally, irisin levels decreased across the clinical stages of diabetic retinopathy
